Contact Us

Contact Us

Please contact us below with any questions

info@quadratech.co.uk

+44 (0)33 3321 2371

Side Contact
×
Sign up to our newsletter Click Here
quadratech Logo
{{ toggleHam ? 'CLOSE' : 'MENU' }}
Next Day & International Delivery
Competitive Pricing
Over 30 Years Experience
Based In The UK

BIOPHEN™ Anti-Xa

X

We're always working hard to give our customers as much information on products and the best price possible. If you need any assistance or would like a quote please contact us and we will be happy to help

BIOPHEN™ Anti-Xa (221005) is a two stages Anti-Xa chromogenic method for the Heparin activity measurement on plasma or purified medium, according to Pharmacopeia (USP, EP). Manufactured by HYPHEN BioMed.

Product Brand:
Product Code: 221005
Description

The BIOPHENTM ANTI-Xa (2 Stages Heparin Assay) kit is a chromogenic anti-Xa method, developed for measuring Unfractionated Heparins (UFH) and Low Molecular Weight Heparins (LMWH) in plasma or in purified solutions, for their Anti-Xa activity. The BIOPHENTM ANTI-Xa (2 Stages Heparin Assay) assay is a method based on the inhibition of a constant amount of Factor Xa (FXa), by the tested heparin in presence of exogenous antithrombin (stage 1), and hydrolysis of a Factor Xa specific chromogenic substrate (CS11(65)), by the Factor Xa in excess (stage 2). pNA is then released from the substrate. The amount of pNA released (measured at 405 nm) is then a relation of the residual Factor Xa activity. There is an inverse relationship between the concentration of heparin and color development. Heparin + AT [AT Hep.] [AT Hep.] + [FXa (excess)]  [FXa-AT-Hep.] + [residual FXa] [residual FXa] + Substrate  Peptide + pNA

Product Specification
Specification Type
Specification Value
Product Range
Product Code
221005
Product Name
BIOPHEN™ Anti-Xa
Product Category
Product Brand
Product Analyte or Application
Product Size
3 x 2 x 1 ml
Product Storage
2°C to 8°C

Our Accreditations

Cookie Consent

Cookies help us deliver our services. By using our services, you agree to our use of cookies.